Asset Details
Do you wish to reserve the book?
Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers
Do you wish to request the book?
Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers
2023
Overview
KCNH2 encodes the human ether-a-go-go-related gene (hERG) potassium channel and is an important repolarization reserve for regulating cardiac electrical activity. Increasing evidence suggests that it is involved in the development of various tumours, yet a thorough analysis of the underlying process has not been performed. Here, we have comprehensively examined the role of KCNH2 in multiple cancers by assessing KCNH2 gene expression, diagnostic and prognostic value, genetic alterations, immune infiltration correlations, RNA modifications, mutations, clinical correlations, interacting proteins, and associated signalling pathways. KCNH2 is differentially expressed in over 30 cancers and has a high diagnostic value for 10 tumours. Survival analysis showed that high expression of KCNH2 was associated with a poor prognosis in glioblastoma multiforme (GBM) and hepatocellular carcinoma (LIHC). Mutations and RNA methylation modifications (especially m6A) of KCNH2 are associated with its expression in multiple tumours. KCNH2 expression is correlated with tumour mutation burden, microsatellite instability, neoantigen load, and mutant-allele tumour heterogeneity. In addition, KCNH2 expression is associated with the tumour immune microenvironment and its immunosuppressive phenotype. KEGG signalling pathway enrichment analysis revealed that KCNH2 and its interacting molecules are involved in a variety of pathways related to carcinogenesis and signal regulation, such as the PI3K/Akt and focal adhesion pathways. Overall, we found that KCNH2 and its interaction molecular are expected to be immune-related biomarkers for cancer diagnosis and prognosis evaluation, and are potential regulatory targets of singalling pathways for tumour development due to their significant role in cancers.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
1-Phosphatidylinositol 3-kinase
/ Biomedical and Life Sciences
/ Cancer
/ Cellular signal transduction
/ Computational Biology/Bioinformatics
/ Computer Appl. in Life Sciences
/ Datasets
/ ERG1 Potassium Channel - genetics
/ ERG1 Potassium Channel - metabolism
/ Ether-A-Go-Go Potassium Channels - genetics
/ Ether-A-Go-Go Potassium Channels - metabolism
/ Humans
/ KCNH2
/ Leukemia
/ Mutation
/ Phosphatidylinositol 3-Kinases - metabolism
/ Potassium channels (voltage-gated)
/ Prostate
/ Proteins
/ RNA
/ Software
/ Tumors
